Drug-induced new onset diabetes in hypertension: Does it matter?

Journal of Hypertension

Volumn 25, Issue 6, 2007, Pages 1201-1204

  Nilsson, Peter M ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT;

ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; EDITORIAL; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; LOW DRUG DOSE; PRIORITY JOURNAL; RETINOPATHY; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE;

EID: 34250322995     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32819f8536     Document Type: Editorial

References (31)

1. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37:1595-1607.
2. DeFronzo R, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic disease. Diabetes Care 1991; 14:173-194.
3. Nilsson P, Lindholm L, Scherstén B. Hyperinsulinemia and other metabolic disturbances in well-controlled hypertensive men and women: an epidemiological study of the Dalby population. J Hypertens 1990; 8:953-959.
4. Kannel WB, Wilson PW, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991; 121:1268-1273.
5. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321:868-873.
6. Lithell HO. Effects of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991; 14:203-209.
7. Jousilahti P, Tuomilehto J, Vartiainen E, Valle T, Nissinen A. Body mass index, blood pressure, diabetes and the risk of anti-hypertensive drug treatment: 12-year follow-up of middle-aged people in eastern Finland. J Hum Hypertens 1995; 9:847-854.
8. Verdecchia P, Reboldi G, Angeli F, Borgioni C, Gattobigio R, Filippucci L, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43:963-969.
9. Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, et al., for the ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166:2191-2201.
10. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR, for the SHEP Collaborative Research Group. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005; 95:29-35.
11. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract 2006; 60:1471-1483.
12. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
13. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al., for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
14. Dahlöf B, Sever P, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366:895-906.
15. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201-207.
16. Nilsson PM, Cifkova R, Kjeldsen SE, Mancia G. European Society of Hypertension Scientific Newsletter: Update on Hypertension Management: Prevention of type 2 diabetes mellitus with antihypertensive drugs. J Hypertens 2006; 24:2478-2482.
17. Almgren T, Wilhelmsen L, Samuelsson O, Himmelmann A, Rosengren A, Andersson OK. Diabetes in treated hypertension is common and carries a high cardiovascular risk. Results from a 28-year follow-up. J Hypertens 2007; 25:1311-1317.
18. Samuelsson O, Pennert K, Andersson O, Berglund G, Hedner T, Persson B, et al. Diabetes mellitus and raised serum triglyceride concentration in treated hypertension - are they of prognostic importance? Observational study. BMJ 1996; 313:660-663.
19. NICE: Hypertension (partial update of CG18): clinical guideline consultation. http://www.nice.org.uk/page.aspx?o=292855 [Accessed June 2006].
20. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996; 101:71S-82S.
21. Nilsson PM, Cifkova R, Kjeldsen SE. Update on Hypertension Management: treatment of hypertension in patients with type 2 diabetes mellitus. J Hypertens 2006; 24:208-210.
22. Berglund G, Andersson O, Widgren B. Low-dose antihypertensive treatment with a thiazide diuretic is not diabetogenic. A 10-year controlled trial with bendroflumethiazide. Acta Med Scand 1986; 220:419-424.
23. MacMahon SW, Macdonald GJ. Antihypertensive treatment and plasma lipoprotein levels. The associations in data from a population study. Am J Med 1987; 80 (suppl 2A):40-47.
24. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276:1886-1892.
25. Alderman MH, Cohen H, Madhavan S. Diabetes and cardiovascular events in diabetes patients. Hypertension 1999; 33:1130-1134.
26. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in the Community Study. N Engl J Med 2000; 342:905-912.
27. Lager I, Blohme G, Smith U. Effect of cardioselective and non selective beta-blockade on the hypoglycemic response in insulin-dependent diabetics. Lancet 1979; 1:458-462.
28. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
29. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J Jr. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990; 11:43-50.
30. Najjar SS, Scuteri A, Lakatta EG. Arterial aging: is it an immutable cardiovascular risk factor? Hypertension 2005; 46:454-462.
31. Nilsson PM. Early vascular ageing and hypertension - a new model for understanding cardiovascular risk. Curr Hypertens Rev 2007; 3:000-000.